BR9907104A - Compostos de 4-(2-ceto-1-benzimidazolinil)piperidina como agonistas do receptor orl1 - Google Patents

Compostos de 4-(2-ceto-1-benzimidazolinil)piperidina como agonistas do receptor orl1

Info

Publication number
BR9907104A
BR9907104A BR9907104-5A BR9907104A BR9907104A BR 9907104 A BR9907104 A BR 9907104A BR 9907104 A BR9907104 A BR 9907104A BR 9907104 A BR9907104 A BR 9907104A
Authority
BR
Brazil
Prior art keywords
receptor agonists
benzimidazolinyl
keto
orl1 receptor
piperidine compounds
Prior art date
Application number
BR9907104-5A
Other languages
English (en)
Inventor
Fumitaka Ito
Hiroshi Kondo
Hirohide Noguchi
Yoriko Ohashi
Tatsuya Yamagishi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9907104A publication Critical patent/BR9907104A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Patente de Invenção: <B>"COMPOSTOS DE 4-(2-CETO-1-BENZIMIDAZOLINIL) PIPERIDINA COMO AGONISTAS DO RECEPTOR ORL1"<D>. Um composto da fórmula: ou os seus sais farmaceuticamente aceitáveis, em que R¹, R², R³, R^ 4^ e R^ 5^ são aqui definidos, são úteis como agonistas do receptor ORL1 e úteis como analgésicos ou semelhantes em indivíduos mamíferos.
BR9907104-5A 1998-01-19 1999-01-08 Compostos de 4-(2-ceto-1-benzimidazolinil)piperidina como agonistas do receptor orl1 BR9907104A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB9800069 1998-01-19
PCT/IB1999/000012 WO1999036421A1 (en) 1998-01-19 1999-01-08 4-(2-keto-1-benzimidazolinyl)piperidine compounds as orl1-receptor agonists

Publications (1)

Publication Number Publication Date
BR9907104A true BR9907104A (pt) 2000-10-24

Family

ID=11004651

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9907104-5A BR9907104A (pt) 1998-01-19 1999-01-08 Compostos de 4-(2-ceto-1-benzimidazolinil)piperidina como agonistas do receptor orl1

Country Status (30)

Country Link
US (1) US6423725B1 (pt)
EP (1) EP1049689B1 (pt)
JP (1) JP3342478B2 (pt)
CN (1) CN1288464A (pt)
AP (1) AP9901442A0 (pt)
AR (1) AR014421A1 (pt)
AT (1) ATE219772T1 (pt)
AU (1) AU1679099A (pt)
BG (1) BG104670A (pt)
BR (1) BR9907104A (pt)
CA (1) CA2317462C (pt)
CO (1) CO4990962A1 (pt)
DE (1) DE69901934T2 (pt)
DK (1) DK1049689T3 (pt)
EA (1) EA200000683A1 (pt)
ES (1) ES2175925T3 (pt)
GT (1) GT199900008A (pt)
IL (1) IL137149A0 (pt)
IS (1) IS5539A (pt)
MA (1) MA26598A1 (pt)
NO (1) NO20003671L (pt)
OA (1) OA11445A (pt)
PA (1) PA8467101A1 (pt)
PE (1) PE20000166A1 (pt)
PL (1) PL342046A1 (pt)
PT (1) PT1049689E (pt)
TN (1) TNSN99006A1 (pt)
TR (1) TR200002090T2 (pt)
WO (1) WO1999036421A1 (pt)
ZA (1) ZA99314B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
EP0997464B1 (en) * 1998-10-23 2005-02-16 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists
AU1185300A (en) * 1998-11-20 2000-06-13 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivatives
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
ES2223588T3 (es) 1999-10-13 2005-03-01 Banyu Pharmaceutical Co., Ltd. Derivados de imidazolidinona sustituidos.
JP4028730B2 (ja) 1999-12-06 2007-12-26 ユーロ−セルティーク エス．エイ． オピオイド受容体に対する親和性を有する３級アミノ化合物
US6686370B2 (en) 1999-12-06 2004-02-03 Euro-Celtique S.A. Triazospiro compounds having nociceptin receptor affinity
EP1242085B1 (en) * 1999-12-06 2005-08-24 Euro-Celtique, S.A. Benzimidazole compounds having nociceptin receptor affinity
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
AU2002224038B2 (en) * 2000-11-15 2006-03-09 Banyu Pharmaceutical Co., Ltd. Benzimidazole derivatives
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
EP1997818A3 (en) 2001-04-18 2009-04-08 Euro-Celtique S.A. Quinolinone derivatives and their use to treat pain
BR0209129A (pt) * 2001-04-18 2005-12-20 Euro Celtique Sa Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
PT1975164E (pt) * 2001-04-18 2010-04-20 Euro Celtique Sa Compostos de octa-hidrobenzimidazolona utilizados como analgésicos
DK1385514T5 (da) 2001-04-18 2009-03-09 Euro Celtique Sa Spiroinden- og spiroindanforbindelser
DK1385515T3 (da) 2001-04-18 2008-10-27 Euro Celtique Sa Spiropyrazole forbindelser
DE10123163A1 (de) * 2001-05-09 2003-01-16 Gruenenthal Gmbh Substituierte Cyclohexan-1,4-diaminderivate
JP3896309B2 (ja) 2001-07-09 2007-03-22 ファイザー株式会社 プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体
PT1491212E (pt) 2002-03-29 2012-11-16 Mitsubishi Tanabe Pharma Corp Medicamento para distúrbios de sono
JP2005289816A (ja) 2002-05-14 2005-10-20 Banyu Pharmaceut Co Ltd ベンズイミダゾール誘導体
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
AU2003296564A1 (en) 2002-11-12 2004-06-03 Grunenthal Gmbh 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives
SA04250305B1 (ar) * 2003-09-25 2008-06-02 سولفاي فارماسوتيكالز بي . في مشتقات بنزيميدازولون cenzimidazolone وكينازولينون quinazolinone كمساعادات على مستقبلات ORL1 البشرية
AR045843A1 (es) * 2003-10-03 2005-11-16 Solvay Pharm Bv Derivados de bencimidazolonas y quinazolinonas sustituidas con hidronopol como agonistas en receptores orl 1 humanos
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
AR054816A1 (es) * 2005-07-13 2007-07-18 Banyu Pharma Co Ltd Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos
US7300947B2 (en) * 2005-07-13 2007-11-27 Banyu Pharmaceutical Co., Ltd. N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives
EP1954137A4 (en) * 2005-11-18 2008-12-17 Janssen Pharmaceutica Nv 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE
EP1987009A1 (en) 2006-01-30 2008-11-05 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
GB0605784D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0605786D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
ATE524180T1 (de) 2006-10-16 2011-09-15 Mitsubishi Tanabe Pharma Corp Mittel zur prophylaxe oder behandlung von alkoholabhängigkeit oder drogenabhängigkeit
KR101370434B1 (ko) * 2007-01-16 2014-03-06 시오노기세이야쿠가부시키가이샤 Ｏｒｌ-1 리간드로서의 헤테로시클릭-치환 피페리딘
MX2009009355A (es) * 2007-03-01 2009-09-11 Mitsubishi Tanabe Pharma Corp Compuesto de bencimidazol y uso farmaceutico del mismo.
KR20140139125A (ko) 2007-08-31 2014-12-04 퍼듀 퍼머 엘피 치환-퀴녹살린-형 피페리딘 화합물 및 그의 용도
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
TW201016675A (en) 2008-09-16 2010-05-01 Mitsubishi Tanabe Pharma Corp Crystalline benzoimidazole compound and salt thereof
EP2582681A1 (en) * 2010-06-17 2013-04-24 Novartis AG Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
US9656994B2 (en) 2013-03-22 2017-05-23 The Scripps Research Institute Substituted benzimidazoles as nociceptin receptor modulators
JPWO2018097291A1 (ja) * 2016-11-28 2019-10-17 田辺三菱製薬株式会社 コカイン依存症の治療または再発予防薬
JP7281469B2 (ja) * 2018-01-19 2023-05-25 イドーシア ファーマシューティカルズ リミテッド Ｃ５ａ受容体調節剤
CN116496270B (zh) * 2022-01-27 2024-09-24 四川大学华西医院 一类4-氨基哌啶衍生物及其制备方法和用途
CN121843930A (zh) * 2024-01-05 2026-04-10 宜昌人福药业有限责任公司 一种环己基取代哌啶衍生物、包含其的药物组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161645A (en) * 1962-12-18 1964-12-15 Res Lab Dr C Janssen N V 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds
US3318900A (en) 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
JPS58180481A (ja) * 1982-04-15 1983-10-21 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
AT388731B (de) 1987-12-15 1989-08-25 Gerot Pharmazeutika Neue derivate von benzimidazol, ihre herstellung und verwendung
WO1997016186A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine agonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
US6180649B1 (en) * 1996-04-19 2001-01-30 Nerosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
US6258825B1 (en) 1997-05-30 2001-07-10 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivatives

Also Published As

Publication number Publication date
IL137149A0 (en) 2001-07-24
EA200000683A1 (ru) 2000-12-25
JP2002509148A (ja) 2002-03-26
CA2317462C (en) 2005-09-13
CN1288464A (zh) 2001-03-21
WO1999036421A1 (en) 1999-07-22
OA11445A (en) 2004-04-30
MA26598A1 (fr) 2004-12-20
TNSN99006A1 (fr) 2005-11-10
AP9901442A0 (en) 1999-03-31
BG104670A (en) 2001-05-31
GT199900008A (es) 2000-07-12
AR014421A1 (es) 2001-02-28
PA8467101A1 (es) 2000-09-29
EP1049689A1 (en) 2000-11-08
ZA99314B (en) 2000-07-18
US6423725B1 (en) 2002-07-23
CA2317462A1 (en) 1999-07-22
AU1679099A (en) 1999-08-02
TR200002090T2 (tr) 2000-11-21
DE69901934D1 (de) 2002-08-01
ES2175925T3 (es) 2002-11-16
IS5539A (is) 2000-06-16
PL342046A1 (en) 2001-05-21
NO20003671D0 (no) 2000-07-18
DK1049689T3 (da) 2002-07-22
EP1049689B1 (en) 2002-06-26
JP3342478B2 (ja) 2002-11-11
PT1049689E (pt) 2002-09-30
NO20003671L (no) 2000-09-18
ATE219772T1 (de) 2002-07-15
CO4990962A1 (es) 2000-12-26
DE69901934T2 (de) 2002-11-07
PE20000166A1 (es) 2000-03-07

Similar Documents

Publication Publication Date Title
NO20003671L (no) 4-(2-keto-1-benzimidazolinyl)piperidin-forbindelser som orl1- reseptor agonister
BRPI0416143A (pt) sais farmaceuticamente aceitáveis de compostos de quinolinona tendo propriedades farmacêuticas aperfeiçoadas
DE60032780D1 (de) Tetrahydroquinolin-derivate
IS6362A (is) Úrea (eða þvagefnis) efnasambönd sem hafa múskarín viðtaka mótlyfs virkni
BR9915403A (pt) Antagonistas receptores iii de 4-aroil-piperidin-ccr-3
DE69522619D1 (de) Heterocyclischer Tachykinin Rezeptor Antagonist
EP1790640A4 (en) NEW IMIDAZOLIDINE DERIVATIVE AND APPLICATION THEREOF
BR9915735A (pt) Antagonistas receptores de ccr-3 de piperidina
BR9916111A (pt) Derivados de fenilglicina
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
BR0017010A (pt) Agentes antibacterianos 3-aminoquinazolin-2,4-diona
BR0014060A (pt) Derivado de quinolil propil piperidina, processo para preparação do mesmo, e, composição farmacêutica
TR200002481T2 (tr) Muskarinik Reseptör antegonistleri olarak 2-ariletil-(piperidin-4-ilmetil) amin türevleri
TR200000786T2 (tr) Vitronektin reseptör antagonisti
BR9813719A (pt) Agentes terapêuticos
BR0014294A (pt) Quinazolinonas
DE60112960D1 (de) Kondensierte pyridoindolderivate
TR200101654T2 (tr) Vitronektin resept”r antagonistleri
BR9912307A (pt) Inibidores fkbp
DE60121048D1 (de) PYRAZINOi1&#39;2&#39;:1,6öPYRIDOi3,4-BöINDOLDERIVATE
NO20006249L (no) Acetylkolinforsterkere
TR200200614T2 (tr) Vitronektin reseptörü antagonistleri
BR0012329A (pt) Derivados de benzofurano
BR9811672A (pt) Derivados de 6-pirrolidin-2-ilpirindinas, seu preparo e sua aplicação em terapêutica
EP1319658A4 (en) IMIDAZOLE DERIVATIVES OR THEIR SALTS

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]